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suggest that n-3 PUFA are associated with a lower incidence of heart failure (HF), although data after AMI are lacking.
9-11
The aim of the present study was to evaluate whether serum DHA and EPA levels are associated with HF-free survival and HF hospitalization rates in AMI survivors enrolled in a multicenter prospective AMI registry in Japan.
Methods

Study Patients and Blood Sampling
The Osaka Acute Coronary Insufficiency Study (OACIS) is a prospective, multicenter observational study that enrolls consecutive patients with AMI in 25 collaborating hospitals from the Osaka region of Japan, and is registered to the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) in Japan (ID: UMIN000004575). Details of OACIS are reported elsewhere. 12, 13 Among 2,579 patients with AMI who were registered in the OACIS between January 2006 and December 2009, we enrolled consecutive 712 patients who were discharged alive and whose blood samples were collected at least 10 days after the onset of AMI and within 14 days before and after discharge. We set the blood sampling period in order to avoid the acute phase impact of AMI (within 10 days after the onset of AMI), and tried to focus on the state of survival discharge (within 14 days before and after discharge). Patient selection flow is shown in Figure S1 ; we excluded 197 cases of in-hospital death, 804 cases without agreement of blood samples, and 866 cases in which samples were not obtained greater than 10 days after the onset of AMI and within 2 weeks before and after discharge from the present study in that order. The diagnosis of AMI was based on the World Health Organization criteria using a combination of patient symptoms, electrocardiographic findings, and serum cardiac enzyme elevations. All study candidates were informed about data collection and blood sampling, and provided written informed consent. Follow-up clinical data were obtained at 3, 6, and 12 months after the onset of AMI and annually thereafter for 5 years. Fasting blood samples were collected at each local hospital. After centrifugation and prompt freezing at −80°C, serum samples were shipped to BML, Inc (Tokyo, Japan) for the measurement of DHA and EPA levels using a gas chromatography method. The study protocol complied with the Helsinki declaration and was approved by each participating institution's ethics committee.
Statistical Analysis
Categorical data are expressed as percentage and differences were analyzed by chi-square statistics. Continuous data are presented as the median (25-75 percentiles) and differences were analyzed by Kruskal-Wallis test or Tukey's test.
We set the primary endpoint as the HF-free survival rate and the secondary endpoints as HF hospitalization and allcause death after survival discharge. The rates of these events were compared by dividing the patients into 3 groups (Low, Middle, and High) based on DHA and EPA tertile levels. The Kaplan-Meier method was used to estimate event rates, and estimated differences were compared by the log-rank test. The effects of DHA and EPA levels on the primary and secondary endpoints were assessed using Cox regression analysis by calculating hazard ratios (HR) and 95% confidence intervals (CI) of the DHA-and EPA-Low groups as compared with the Middle and High groups. Furthermore, to reduce possible confounding factors regarding patient background in the comparison, the survival function of event rates for the DHA-and EPA-Low groups was compared with the other groups by stratified log-rank test, where the strata classification was based on propensity scores. 14 Propensity scores were calculated by logistic regression analysis including the DHA-and EPA-Low groups as the response variable, and age, sex, ST-elevation MI, diabetes, hypertension, dyslipidemia, smoking, old MI, estimated glomerular filtration rate, reperfusion therapy, statin, angiotensin-converting enzyme inhibitor or angiotensin 2 receptor blocker, β-blocker, and antiplatelet agents as explanatory variables. Thus, all the abovementioned variables, which were used in the propensity score calculation, were adjusted during propensity-score-stratified analysis. The statistical significance was set as P<0.05. All statistical analyses were performed using R software ver.2.13.1 (http://cran.r-project.org/).
Results
The patients' backgrounds are shown in and ethyl icosapentate were 60.5%, 82.3%, 67.0%, 99.0%, and 2.5%, respectively. Ethyl icosapentate is the only available EPA formulation, and there is no available DHA formulation with medical care insurance in Japan. In the present study, there were no available data regarding over-the-counter DHA or EPA supplement capsule usage, and no available data regarding the amount of daily fish intake. Possible selection bias was evaluated by comparing the patients' backgrounds among the enrolled patients (Subject group: n=712) and those not enrolled because of a lack of eligible serum samples (No-sample group: n=866) or a lack of the agreement of blood samples (No-agreement group: n=804). As shown in Table S1 , patients' backgrounds differed significantly between the Subject and No-agreement groups, but were almost comparable between the Subject and No-sample groups, except for the duration of follow-up period and prevalences of dyslipidemia, smoking and ST-elevation MI.
Blood samples were obtained from patients at a median of 17 (quartile: 13-24) days after the onset of AMI. The distribution of serum DHA and EPA levels is shown in Figure 1 . Based on the DHA tertile values, we grouped patients with DHA ≤61.4 μg/ml into a DHA-Low group (n=239), those with DHA >83.5 μg/ml formed the DHA-High group (n=237), and those with intermediate serum levels comprised the DHAMiddle group (n=236; Table 2 ). We also defined patients with serum EPA levels of ≤24.6 μg/ml as the EPA-Low group (n=237), those with EPA levels of >38.8 μg/ml as the EPAHigh group (n=238), and all others as the EPA-Middle group (n=237) according to EPA tertile values ( Table 3) . A strong correlation was detected between the DHA and EPA values based on the Spearman's rank correlation coefficient of r=0.708 (P<0.0001).
Event rates were compared among the DHA and EPA groups by Kaplan-Meier analysis (Figure 2 ). There were a total of 35 HF hospitalizations and 45 all-cause death events (17 HF and 23 deaths in the DHA-Low group, 10 HF and 12 deaths in the DHA-Middle group, and 8 HF and 10 deaths in the DHAHigh group; 20 HF and 19 deaths in the EPA-Low group, 7 HF and 16 deaths in the EPA-Middle group, and 8 HF and 10 deaths in the EPA High group) at the median follow-up duration of 1,079 (quartile: 721-1,442) days. There were 9 cardiovascular, 19 non-cardiovascular, and 17 unknown-cause deaths in the present study.
Both the DHA-and EPA-Low groups showed statistically significant worse HF-free survival as compared with the other groups (P=0.0204 and P=0.0353, respectively; Figures 2A,B) . However, when we focused on each event rate, the EPA-Low group displayed a statistically significant worse outcome only for HF hospitalizations (P=0.0086; Figures 2C,D) , while the DHA-Low group exhibited an adverse outcome only for all- Figures 2E,F) . Cause-specific cumulative death event rates among tertile groups of DHA or EPA were also evaluated ( Figure S2) . However, there were no statistical differences in event rates among the tertile groups of DHA or EPA possibly because of the low event rates.
Similar results to the Kaplan-Meier analyses were found by propensity-score-stratified Cox regression analysis (Figures 3-5) , which revealed that low serum levels of DHA and EPA were both associated with a higher incidence of the composite of all-cause death and HF hospitalization at nearly the same 
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significance level (HR 1.68, P=0.0358 for DHA; and HR 1.69, P=0.0280 for EPA) (Figure 3) . However, low serum EPA was only associated with a higher risk of HF hospitalization (HR 2.40, P=0.0097) (Figure 4) , whereas low DHA was only associated with a higher risk of all-cause death (HR 1.91, P=0.0386) ( Figure 5) . Thus, EPA appeared to be superior to DHA for estimating HF event risk after AMI whereas DHA appeared to be superior to EPA for estimating all-cause mortality after AMI. Subgroup analyses demonstrated that the unfavorable effect Figure 3 . Results of Cox regression analysis for composite endpoint consisting of all-cause death and heart failure hospitalization. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin 2 receptor blocker; BB, β-blocker; CI, confidence interval; DHA, docosahexaenoic acid; DL, dyslipidemia; e-GFR, estimated glomerular filtration rate; EPA, eicosapentaenoic acid; HDL-chol, high-density lipoprotein cholesterol; HF, heart failure; HR, hazard ratio; LDL-chol, low-density lipoprotein cholesterol; PS, propensity score; T-chol, total cholesterol; TG, triglyceride.
159 Serum n-3 PUFA and HF Risk After AMI of a low DHA or EPA serum level on the primary and secondary endpoints was generally common for all subgroups, with a few notable exceptions. For example, it was revealed that the effect of low EPA levels on HF hospitalizations was prominent in male patients (P for interaction=0.0081), those with low high-density lipoprotein (HDL) cholesterol levels (P for interaction=0.0344), and those without statin therapy (P for interaction=0.0482) (Figure 4) . On the other hand, the effect of low DHA levels on all-cause death was common to all subgroups ( Figure 5) . Results of Cox regression analysis for heart failure hospitalization. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin 2 receptor blocker; BB, β-blocker; CI, confidence interval; DHA, docosahexaenoic acid; DL, dyslipidemia; e-GFR, estimated glomerular filtration rate; EPA, eicosapentaenoic acid; HDL-chol, high-density lipoprotein cholesterol; HF, heart failure; HR, hazard ratio; LDL-chol, low-density lipoprotein cholesterol; PS, propensity score; T-chol, total cholesterol; TG, triglyceride.
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Discussion
In the present study, we observed that low levels of both DHA and EPA were associated with a worse HF-free survival rate in the secondary prevention setting after AMI. In addition, an association with a higher risk of HF hospitalization was prominent for lower serum EPA levels, whereas there was a higher mortality risk with lower DHA. Although the effects of n-3 PUFA on atherosclerotic cardiovascular events have been intensively investigated, limited data are available regarding their salutary effect on the incidence of HF. To our knowledge, this is the first study to reveal the association between Figure 5 . Results of Cox regression analysis for all-cause death. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin 2 receptor blocker; BB, β-blocker; CI, confidence interval; DHA, docosahexaenoic acid; DL, dyslipidemia; e-GFR, estimated glomerular filtration rate; EPA, eicosapentaenoic acid; HDL-chol, high-density lipoprotein cholesterol; HF, heart failure; HR, hazard ratio; LDL-chol, low-density lipoprotein cholesterol; PS, propensity score; T-chol, total cholesterol; TG, triglyceride. Serum n-3 PUFA and HF Risk After AMI decreased n-3 PUFA levels and worse HF-free survival in the secondary prevention setting after AMI. In addition, even though the relationship and underlying mechanisms remain unclear, our results also indicate that monitoring EPA serum levels may be useful for predicting HF events and monitoring DHA serum levels may be useful for predicting all-cause mortality following AMI. However, it should be noted that the EPA level also could be useful for predicting all-cause mortality if we change the cut-off level. As shown in Figure 2F , all-cause mortality estimate was clearly discerned between the lower 2 EPA tertile groups vs. the highest EPA tertile group, suggesting that the EPA level could be useful for estimating the allcause mortality risk if we set the cut-off between the lower 2 tertiles and the highest tertile. These observations are consistent with a recent report by Mozaffarian et al showing that total and individual n-3 PUFA concentrations are associated with incident congestive HF in the United States elderly population, with EPA having the highest correlation with HF events. 11 In comparison, 2 recently published large-scale randomized clinical trials of n-3 PUFA supplementation failed to demonstrate beneficial effects on major cardiovascular events in a secondary prevention setting after AMI, although they did not assess incidence of HF. 3, 4 Those trials may suggest that contemporary evidence-based medications such as angiotensin-converting enzyme inhibitor or statins can surpass the beneficial effects of n-3 PUFA. Indeed, our result of subgroup analysis suggested that the beneficial effects of DHA and EPA on HF-free survival and HF hospitalization were mostly prominent in patients not treated with such medications (but not on all-cause death). Thus, it should be noted that effect of n-3 PUFA levels on cardiac events in patients administered recent evidence-based medications needs to be evaluated further, and we also emphasize that the benefit of n-3 PUFA should be determined in patients for whom these state-of-the-art medications are not available because of adverse effects or other reasons. 3, 4 The beneficial effect of both DHA and EPA in reducing HF hospitalizations and all-cause death after AMI is intuitively plausible considering the evidence for the cardiac benefits of n-3 PUFA intake. 1,2,10,15-21 For example, n-3 PUFA supplementation improves myocardial efficiency by reducing myocardial oxygen demand without a decrement in performance and clinically improves the left ventricular ejection fraction in patients with dilated cardiomyopathy or chronic HF. 10,15, 16 In addition, n-3 PUFA intake is associated with lower blood pressure and heart rate. 17, 18 Together these lines of evidence for the usefulness of n-3 PUFA supplementation in cardiovascular protection strongly support our observation that low levels of n-3 PUFA were associated with worse HF-free survival in patients with AMI.
In the subgroup analyses, the unfavorable effects of low serum DHA or EPA levels on HF-free survival appeared to be common to all of the subgroups, even for patients with wellcontrolled low-density lipoprotein (LDL) levels (<100 mg/dl). However, we also observed an inverse relationship between EPA level and the incidence of HF hospitalization prominently in male patients, patients with low HDL cholesterol levels, and those not receiving statin therapy. Thus, EPA supplementation following AMI may be beneficial for preventing HF hospitalization in these subpopulations, although the evidence is not yet available. Even though the salutary effects of n-3 PUFA supplementation on clinical outcomes have been demonstrated in patients with chronic HF, 9,10 an inverse correlation between serum EPA levels and HF risk after AMI has not been reported previously.
On the basis of currently available evidence, the American Heart Association recommends that patients with documented coronary heart disease consume approximately 1 g/day of DHA and EPA (combined) obtained from fish or fish-oil capsules. 22 Because our data suggest that EPA may be beneficial in preventing HF hospitalization and DHA in preventing all-cause death after AMI, the beneficial effects of higher serum levels of EPA and DHA on the secondary prevention of HF and allcause death after AMI should be further studied in a randomized control trial.
Study Limitations
Our study has a few limitations that warrant mention. First, the measurement of serum n-3 PUFA levels was a 1-point assessment at discharge, and did not reflect temporal changes and everyday consumption of n-3 PUFA. This might lead to inaccurate estimation of the association between n-3 PUFA and HF events. In addition, because there were no available data regarding n-3 PUFA consumption, the association between serum n-3 PUFA levels and daily intake of n-3 PUFA could not be assessed. Second, there could be a selection bias in the present study as shown in Table S1 . Third, it is possible that unmeasured confounding factors influenced the study outcomes because of the inherent nature of observational studies. In this regard, the data should be interpreted with caution.
Conclusions
Low levels of serum n-3 PUFA were associated with worse HF-free survival in patients with AMI. Notably, low levels of EPA and DHA were particularly associated with HF hospitalization and all-cause mortality, respectively.
